Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the transaction, the insider now owns 6,887 shares in the company, valued at $318,454.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.45, for a total value of $2,286,779.95.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total value of $92,364.06.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $44.50 on Wednesday. The firm has a market capitalization of $2.31 billion, a PE ratio of -36.48 and a beta of 3.57. The business’s fifty day moving average price is $43.85 and its 200 day moving average price is $44.68. Janux Therapeutics, Inc. has a 12 month low of $5.65 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The company’s revenue for the quarter was up 709.1% compared to the same quarter last year. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently bought and sold shares of the stock. Capstone Investment Advisors LLC acquired a new position in Janux Therapeutics in the first quarter valued at $1,969,000. Janus Henderson Group PLC boosted its stake in Janux Therapeutics by 1.8% in the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after acquiring an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Janux Therapeutics in the first quarter valued at $739,000. Virtu Financial LLC acquired a new position in Janux Therapeutics in the first quarter valued at $609,000. Finally, Vanguard Group Inc. boosted its stake in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a research report on Monday, August 19th. Scotiabank cut their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Stifel Nicolaus assumed coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $66.13.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.